The aim of the present work was to investigate the in vivo hepatoprotective potential of coumarinolignoids (cleomiscosins A, B, and C) isolated from the seeds of C. viscosa. The study was performed against CCl4-induced hepatotoxicity in albino rats. Rats were divided into four groups. The animals of group I served as normal and was given only vehicle. Group II served as toxin control and administered with CCl4 (50% solution liquid paraffin, 2 ml/kg intraperitoneally). The animals of group III received coumarinolignoids (50 mg/kg) for six days orally as well as CCl4 (2 ml/kg) on 4th day i.p. Similarly animals of group IV received silymarin (50 mg/kg) for six days orally as well as CCl4 on 4th day i.p. On 7th day various parameters viz. serum glutamyl oxaloacetic transaminase, serum glutamyl pyruvate transaminase, serum alkaline phosphatase, serum bilirubin, liver glycogen were estimated and histopathology was performed. Additionally, acute oral toxicity of the said coumarinolignoids was carried out in swiss albino mice. The coumarinolignoids were found to be effective as hepatoprotective against CCl4-induced hepatotoxicity as evidenced by in vivo and histopathological studies in small animals. Safety evaluation studies also exhibit that coumarinolignoids are well tolerated by small animals in acute oral toxicity study except minor changes in red blood cell count and hepatic protein content at 5000 mg/kg body weight as a single oral dose. Coumarinolignoids which is the mixture of three compounds (cleomiscosin A, B and C) is showing the significant protective effects against CCl4-induced hepatotoxicity in small animals and also coumarinolignoids are well tolerated by small animals in acute oral study.

Background: Hepatotoxicity is one of the common side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Scientific study stated that hepatotoxicity is the most serious adverse effects of Aceclofenac. Objectives: In this study, our aim was to investigate the use of Fortibile® tablet containing ursodeoxycholic acid (UDCA) in prevention of the hepatotoxic effect and biochemical changes induced by aceclofenac (ACE) in laboratory mice. Materials and Methods: Swiss albino mice were divided into four groups (control, UDCA (Fortibile® tablet) 20 mg/kg, aceclofenac (ACE) 50mg/kg, UDCA 20 mg/kg + aceclofenac 50 mg/kg). Results: Administration of aceclofenac (ACE) showed decline body weight, food consumption, water intake and elevated liver weight in mice whereas treatment with UDCA (Fortibile® tablet) normalized the same as compared with untreated animals. Animals treated with aceclofenac caused elevated activities of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) as well as total and direct bilirubin level. These elevations in liver enzymes were decreased by combination of aceclofenac with UDCA. On the other hand application of aceclofenac (ACE) on mice caused a significant increase in serum and tissue malondialdehyde (MDA) and nitric oxide (NO) content but significant decrease in glutathione GSH and GPx content. Combine thepary of UDCA and aceclofenac resulted in a significant decrease in MDA, NO content and significantly elevated GSH and GPx content. Conclusion: It could be concluded that Fortibile® tablet containing Ursodeoxycholic acid acts as an effective hepatoprotective agent against NSAIDs induced liver dysfunction, and this effect might be related to its antioxidant properties. Hepatic functions should be monitored, and the dose should be adjusted during aceclofenac (ACE) therapy. Keywords: Ursodeoxycholic acid, Aceclofenac, Hepatotoxicity, Liver function test, Oxidative stress,

SummaryRats were subjected to the following procedures: No treatment, Stressor (10% NaCl i.p.), Warfarin for 7 days, Stressor followed by Warfarin; and groups were sacrificed at intervals for assessment of spontaneous hemorrhage and of adrenal ascorbic acid concentration. There was no hemorrhage in the no treatment and stressor groups; some hemorrhage in the warfarin group; profound hemorrhage with Warfarin + Stressor. The adrenal ascorbic acid concentration was found to be lower, 8 h and again 5 days after stress, and remained lower in the warfarin + stress animals. Warfarin had no effect on adrenal ascorbic acid level.In another series of experiments in which the stress consisted of an electric current to the cage floor for 6 sec over 15 min, rats were sacrificed daily for determination of serum corticosterone concentration and occurrence of spontaneous hemorrhage. There was a statistically significant increase of serum corticosterone concentration with stress, warfarin and combined warfarin and stress treatments (P< 0.001 for all three variables). There was a significant correlation (r = 0.96 and 0.89, P< 0.01) for serum corticosterone concentration with hemorrhage score and incidence of hemorrhage in stressed rats receiving warfarin, but not in those receiving only warfarin. The results indicate an activation, rather than an exhaustion, of the pituitary-adrenal axis during the combined action of anticoagulant and stress, which results in the development of spontaneous hemorrhage.

In the safety evaluation of a test substance, determination of acute oral toxicity is generally the initial step and provides information on health hazards that may arise from an acute exposure by the oral route. It may also provide early information on the mode of toxic action of a substance. The study was aimed to assess the possible toxic effects and to identify the preliminary safety profile of Trasina®, a polyherbal capsule (M/S Dey's Medical Stores Manufacturing Limited, Kolkata, West Bengal, India) after single oral administration in mice according to the OECD guidelines. In the present study, a single administration of the poly herbal extract at a dose of 2000 mg/kg, respectively, was given to the swiss albino mice. During the study period the mice were observed for general appearance, behavior, body weight, adverse effects, mortality and necropsy up to 14 days post-treatment. No toxicological changes or mortalities related to the test substance were also observed after the administration in experimental animals. No changes in general appearance and mortality was observed. Trasina was found to be safe at dose of 2000 mg/kg. In the conclusion these results demonstrate that the extract may not have any single dose toxicity.